ONCY ONCOLYTICS BIOTECH INC revenue, earnings and financials
For the quarter ended June 30, 2026, ONCOLYTICS BIOTECH INC reported revenue of n/a, net income of −$9.44M and diluted EPS of −$0.08; for the fiscal year ended December 2025 revenue was n/a.
ONCY annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$28.7M, net income −$28.8M (margin n/a), EPS −$0.30
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$25.5M, net income −$22.8M (margin n/a), EPS −$0.30
ONCY quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$9.44M, EPS −$0.08
- Quarter ended Mar 31, 2026: revenue n/a, net income −$9.24M, EPS −$0.08
- Quarter ended Jun 30, 2025: revenue n/a, net income −$5.28M, EPS −$0.06
- Quarter ended Mar 31, 2025: revenue n/a, net income −$4.71M, EPS −$0.06
ONCY cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$20.1M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$19.9M, share buybacks n/a
ONCY balance sheet
- Jun 30, 2026: cash $4.12M, total assets $7.67M, total liabilities $13.8M, shareholders' equity −$6.17M
- Mar 31, 2026: cash $5.49M, total assets $8.16M, total liabilities $13.3M, shareholders' equity −$5.13M
- Dec 31, 2025: cash $5.20M, total assets $7.58M, total liabilities $11.4M, shareholders' equity −$3.80M
- Dec 31, 2024: cash $11.1M, total assets $13.4M, total liabilities $10.1M, shareholders' equity $3.30M
Is ONCY profitable?
No. ONCOLYTICS BIOTECH INC lost $28.8M in its latest fiscal year.